Companies / Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc.
Nasdaq: CLDXCIK 744218HAMPTON, NJ
Financials · FY2025
Ownership
78.5M shares outstanding · as of Jul 29, 2026
Ownership
| Insiders | 0.04% | 32,942 |
| 10%+ / strategic | 4.33% | 3,397,713 |
| Institutions | 91.58% | 71,920,426 |
| Public float | 4.05% | 3,178,451 |
% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.
Insiders 5
View all →| Insider | % of shares | Shares |
|---|---|---|
Martin Samuel BatesSVP AND CFO | 0.04% | 32,942 |
Conrad Herbert JDirector | — | — |
Marino James JDirector | — | — |
Penner Harry JrDirector | — | — |
Pepin RonaldSR. VP & CBO | — | — |
Institutional holders 199
View all →| Holder | Value | % of shares |
|---|---|---|
| $260.56M | 8.92% | |
| $219.44M | 10.29% | |
| $161.42M | 7.57% | |
| $145.13M | 4.97% | |
| $133.29M | 6.25% | |
| $109.38M | 5.13% | |
| $98.26M | 4.61% | |
| $69.67M | 3.27% | |
| $53.56M | 2.15% | |
| $51.62M | 2.42% |
Activity
Jun 30, 2026View all →
InsidersInstitutions
Who's accumulating and trimming this stock (13F).| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Q2 2026 as of | BlackRock, Inc. 13F manager | Add | Common stock | $57.70M | +1.6M +28.44% | 7,002,530 8.92% of shares | high |
| Q2 2026 as of | State Street Corporation 13F manager | Add | Common stock | $18.71M | +503K +14.80% | 3,900,427 4.97% of shares | medium |
| Q1 2026 as of | Palo Alto Investors LP 13F manager | New | Common stock | $9.40M | +296K | 296,408 0.38% of shares | medium |
| Q1 2026 as of | Segall Bryant & Hamill, LLC 13F manager | Trim | Common stock | $-5.32M | -168K -32.58% | 346,919 0.44% of shares | medium |
| Q1 2024 as of | Barclays PLC 13F manager | Trim | Common stock | $-3.32M | -79K -54.27% | 66,714 0.08% of shares | low |
| Q1 2026 as of | Renaissance Technologies LLC 13F manager | Exit | Common stock | $-3.22M | -118K -100.00% | 0 | low |
| Q2 2025 as of | Barclays PLC 13F manager | Add | Common stock | $2.97M | +146K +125.39% | 262,725 0.33% of shares | low |
| Q1 2026 as of | Balyasny Asset Management L.P. 13F manager | New | Common stock | $2.70M | +85K | 85,026 0.11% of shares | low |
5%+ ownership events
Schedule 13D / 13G
| Filer | Stance | % of class |
|---|---|---|
| Vanguard Group Inc | Passive13G/A | — |
| Point72 Asset Management, L.P. | Passive13G/A | — |
| Wellington Management Group LLP | Passive13G/A | — |
| State Street Corporation | Passive13G | — |
Securities
via CUSIP / OpenFIGI
| Symbol | Type | CUSIP |
|---|---|---|
| CLDX | — | 15117B202 |